Novartis has entered a global licensing and collaboration agreement with Arrowhead Pharmaceuticals to develop RNA interference therapies utilizing Arrowhead's Targeted RNAi Molecule (TRiM) platform. The lead asset, ARO-SNCA, targets alpha-synuclein implicated in synucleinopathies such as Parkinson’s disease. This partnership reflects a strategic push to harness innovative RNA-based mechanisms to address unmet needs in neurodegenerative disorders, with Novartis leveraging Arrowhead's subcutaneous delivery technology to facilitate brain penetration.